Videos
Second-Line Therapy in Extranodal Marginal Zone Lymphoma
Perspective on Treating Advanced Marginal Zone Lymphoma
David O’Malley, MD, a professor in the Department of Obstetrics and Gynecology at The Ohio State University Comprehensive Cancer Center, discusses the results seen so far with the combination of bevacizumab plus mirvetuximab soravtansine, an antibody-drug conjugate, in patients with platinum-resistant ovarian cancer.
Lung Cancer
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oral Azacitidine-Cedazuridine Meets Pharmacokinetic Goal in Phase 3 MDS/CMML Trial
2
Q4 2026 Oncology Outlook: Key FDA Decisions to Watch
3
Bianchi Highlights Personalized Therapy as the Next Frontier in Myeloma and Amyloidosis
4
Zabilugene Almadenorepvec Plus Chemo Shows Survival Gains in Metastatic PDAC
5